Dr. Gill is CEO of Evelo and Sr. Partner at Flagship Ventures. He has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, gene therapy and immunodiagnostics. These companies include Maxygen, Verdia, Avidia, Systemix and Valentis.
Dr. Gill was a Partner at TPG, focused on investments in Life Sciences and Emerging Markets and was also CEO of moksha8, a Latin American specialty pharmaceutical company focused on CNS diseases.
Early in his career, while at Boehringer Mannheim (now Roche), Dr. Gill was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys immunodiagnostics system.
Dr. Gill has an MBA from INSEAD and carried out his PhD with focus on developing humanized antibodies to treat cancer. This work was done at King's College, London in collaboration with Celltech.